[18F]FAPI-74 PET 在多种组织病理学确诊癌症及良性病变中的初步评估
研究纳入31例组织病理学确诊或疑似恶性肿瘤患者,初步评估[18F]FAPI-74 PET的诊断表现。原发恶性病变摄取高于非恶性病变但未达统计学显著(中位SUVmax 9.39 vs 3.49,P=0.053);与[18F]FDG PET相比,[18F]FAPI-74 PET在原发灶、淋巴结转移及其他转移灶摄取均显著更高。
要点
- [18F]FAPI-74 PET在原发恶性病变摄取高于非恶性病变但未达统计学显著。
- [18F]FAPI-74 PET在原发灶、淋巴结转移及其他转移灶摄取均显著高于[18F]FDG PET。
- 6例患者中[18F]FAPI-74 PET检出的转移灶数量多于[18F]FDG PET。
核心结论
- [18F]FAPI-74 PET在原发和转移性病变中显示出比[18F]FDG PET更高的摄取和检出率。
- [18F]FAPI-74 PET是多种肿瘤有前景的新型诊断手段,尤其适用于治疗前精确分期,包括术前肿瘤病变特征描述。
- 18F标记的FAPI配体未来可能满足更高的临床需求。
研究设计与样本
- 前瞻性初步评估研究,纳入31例患者(男17例、女14例),包括肺癌7例、乳腺癌5例、胃癌5例、胰腺癌3例、其他癌症5例及良性肿瘤6例。
- 31例中27例为初治或术前,其余4例怀疑复发;29例原发灶获得组织病理学确认,其余2例最终诊断基于临床病程。
- 静脉注射[18F]FAPI-74(240 ± 31 MBq)后60分钟行PET扫描。
- 比较恶性肿瘤原发或局部复发灶(n=21)与非恶性病变(n=8:B1型胸腺瘤、肉芽肿、孤立性纤维瘤及术后或治疗后改变)的摄取。
- 对可行[18F]FDG PET的患者(n=19)比较两种示踪剂的摄取及检出病灶数量。
主要发现
- [18F]FAPI-74 PET在原发恶性病变的中位SUVmax为9.39(范围1.83-25.28),非恶性病变为3.49(范围2.21-15.58),P=0.053,未达统计学显著;部分非恶性病变显示高摄取。
- 原发灶中位SUVmax:[18F]FAPI-74 PET 9.44(范围2.50-25.28)vs [18F]FDG PET 5.45(范围1.22-15.06),P=0.010。
- 淋巴结转移中位SUVmax:[18F]FAPI-74 PET 8.86(范围3.51-23.33)vs [18F]FDG PET 3.84(范围1.01-9.75),P=0.002。
- 其他转移灶中位SUVmax:[18F]FAPI-74 PET 6.39(范围0.55-12.78)vs [18F]FDG PET 1.88(范围0.73-8.35),P=0.046。
- 6例患者中[18F]FAPI-74 PET检出的转移性病灶数量多于[18F]FDG PET。
临床怎么用
- 作者认为[18F]FAPI-74 PET是多种肿瘤有前景的新型诊断手段,尤其适用于治疗前精确分期,包括术前肿瘤病变特征描述。
- 作者认为18F标记的FAPI配体未来可能满足更高的临床需求。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 18F-labeled fibroblast activation protein inhibitor (FAPI) [18F]FAPI-74 has the benefit of a higher synthetic yield and better image resolution than 68Ga-labeled FAPI. We preliminarily evaluated the diagnostic performance of [18F]FAPI-74 PET in patients with various histopathologically confirmed cancers or suspected malignancies. Methods: We enrolled 31 patients (17 men and 14 women) with lung cancer (n = 7), breast cancer (n = 5), gastric cancer (n = 5), pancreatic cancer (n = 3), other cancers (n = 5), and benign tumors (n = 6). Twenty-seven of the 31 patients were treatment-naïve or preoperative, whereas recurrence was suspected in the remaining 4 patients. Histopathologic confirmation was obtained for the primary lesions of 29 of the 31 patients. In the remaining 2 patients, the final diagnosis was based on the clinical course. [18F]FAPI-74 PET scanning was performed 60 min after the intravenous injection of [18F]FAPI-74 (240 ± 31 MBq). The [18F]FAPI-74 PET images were compared between the primary or local recurrent lesions of malignant tumors (n = 21) and nonmalignant lesions (n = 8: type-B1 thymomas, granuloma, solitary fibrous tumor, and postoperative or posttherapeutic changes). The uptake and number of detected lesions on [18F]FAPI-74 PET were also compared with those on [18F]FDG PET for available patients (n = 19). Results: [18F]FAPI-74 PET showed higher uptake in primary lesions of various cancers than in nonmalignant lesions (median SUVmax, 9.39 [range, 1.83-25.28] vs. 3.49 [range, 2.21-15.58]; P = 0.053), but some of the nonmalignant lesions showed high uptake. [18F]FAPI-74 PET also showed significantly higher uptake than [18F]FDG PET (median SUVmax, 9.44 [range, 2.50-25.28] vs. 5.45 [range, 1.22-15.06] in primary lesions [P = 0.010], 8.86 [range, 3.51-23.33] vs. 3.84 [range, 1.01-9.75] in lymph node metastases [P = 0.002], and 6.39 [range, 0.55-12.78] vs. 1.88 [range, 0.73-8.35] in other metastases [P = 0.046], respectively). In 6 patients, [18F]FAPI-74 PET detected more metastatic lesions than [18F]FDG PET. Conclusion: [18F]FAPI-74 PET showed higher uptake and detection rates in primary and metastatic lesions than did [18F]FDG PET. [18F]FAPI-74 PET is a promising novel diagnostic modality for various tumors, especially for precise staging before treatment, including characterization of tumor lesions before surgery. Moreover, 18F-labeled FAPI ligand might serve a higher demand in clinical care in the future.
引用
- Watabe T, Naka S, Tatsumi M, et al. Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions. J Nucl Med. 2023. PMID: 37268427. doi:10.2967/jnumed.123.265486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。